Join
Live feed
·
PRReleasevia Quantisnow
Foghorn Therapeutics Inc. logo

Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
FHTX· Foghorn Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track FHTX (Foghorn Therapeutics Inc.) and more on Quantisnow.